The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.59 USD
+0.09 (0.08%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $106.55 -0.04 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
LH vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
XRAY vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
HSIC or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
4 Stocks to Keep a Watch on Amid Growing Optical Care Demand
by Riya Anand
Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.
Cooper Companies (COO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
The Cooper Companies (COO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 3.33% and 5.36%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?
Why The Cooper Companies (COO) Might Surprise This Earnings Season
by Aditi Saraogi
The Cooper Companies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
The Cooper Companies (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will The Cooper Companies (COO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
The Cooper Companies (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Cooper Companies (COO) Unit's MiSight Gets Approval in China
by Zacks Equity Research
CooperVision, a unit of Cooper Companies (COO), receives approval for MiSight 1 day contact lenses from China's National Medical Products Administration for use in China.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
Strength Seen in The Cooper Companies (COO): Can Its 7.8% Jump Turn into More Strength?
by Zacks Equity Research
The Cooper Companies (COO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
HSIC vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.
Abbott (ABT) Downgrades 2021 Outlook on Lower Testing Demand
by Zacks Equity Research
Abbott's (ABT) revised 2021 forecast continues to reflect strong, double-digit EPS growth despite lower COVID-19 testing demand.
Myriad Genetics (MYGN) Sells myPath to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will provide the company with growth capital for future investments.
Quest Diagnostics (DGX) Buys Outreach Lab, Widens Midwest Base
by Zacks Equity Research
Mercy's outreach laboratory services are set to get integrated into Quest Diagnostics' (DGX) full-service laboratory in Lenexa, KS.
Integra (IART) Tissue Technologies Rebounds Amid Supply Woe
by Zacks Equity Research
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.